Clinical trials

See also

References

1. ^^abde Paulis T (2007). "Drug evaluation: PRX-00023, a selective 5-HT1A receptor agonist for depression".Curr Opin Investig Drugs.8 (1):78–86.PMID 17263189.
2. ^^abcdeRickels K, Mathew S, Banov MD, Zimbroff DL, Oshana S, Parsons EC, Donahue SR, Kauffman M, Iyer GR, Reinhard JF (2008). "Effects of PRX-00023, a novel, selective serotonin 1A receptor agonist on measures of anxiety and depression in generalized anxiety disorder: results of a double-blind, placebo-controlled trial".J Clin Psychopharmacol.28 (2):235–239.doi:10.1097/JCP.0b013e31816774de.PMID 18344738.S2CID 40515142.
3. ^Becker OM, Dhanoa DS, Marantz Y, Chen D, Shacham S, Cheruku S, Heifetz A, Mohanty P, Fichman M, Sharadendu A, Nudelman R, Kauffman M, Noiman S (2006). "An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment of anxiety and depression".J Med Chem.49 (11):3116–3135.doi:10.1021/jm0508641.PMID 16722631.
4. ^^abIyer GR, Reinhard JF, Oshana S, Kauffman M, Donahue S (2007). "Tolerability, pharmacokinetics, and neuroendocrine effects of PRX-00023, a novel 5-HT1A agonist, in healthy subjects".J Clin Pharmacol.47 (7):817–824.doi:10.1177/0091270007300953.PMID 17495280.S2CID 30536648.
5. ^Prof John Kelly (2010).Principles of CNS Drug Development: From Test Tube to Patient. New York: Wiley.ISBN 978-0-470-51979-0.
6. ^Mathew SJ, Garakani A, Reinhard JF, Oshana S, Donahue S (2008). "Short-term tolerability of a nonazapirone selective serotonin 1A agonist in adults with generalized anxiety disorder: a 28-day, open-label study".Clin. Ther.30 (9):1658–1666.doi:10.1016/j.clinthera.2008.09.006.PMID 18840371.
7. ^^abKirchhoff VD, Nguyen HT, Soczynska JK, Woldeyohannes H, McIntyre RS (October 2009)."Discontinued psychiatric drugs in 2008".Expert Opinion on Investigational Drugs.18 (10):1431–43.doi:10.1517/13543780903184591.PMID 19715445.S2CID 34201544.